ea0038p93 | Clinical practice/governance and case reports | SFEBES2015
Hayden Jennifer
, Huang Feicong
, McConnell Lyndsey
, Sainsbury Christopher
, Jones Gregory
Background: Dapagliflozin was the first SGLT2 inhibitor licensed in UK to improve glycaemic control in type 2 diabetes. Whilst it has not been studied for use in combination with GLP1 agonists the modes of action of the two therapies suggest they would be a logical therapeutic combination. We aimed to evaluate clinical experience with this regimen.Methods: Observational retrospective data was collected from electronic patient records (SCIĀdiabetes) ...